Significant Ownership of Commodore Capital LP

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for Commodore Capital LP focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
Michael Kramarz - Managing Partner
Manager location
New York, NY

Follow Filing Activity

Follow Commodore Capital LP and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Significant Ownership of Commodore Capital LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RLAY Relay Therapeutics, Inc. Common Stock, par value $0.0001 per share 9.9% $88,740,000 +$19,053,000 17,000,000 +27% Commodore Capital LP 30 Sep 2025
ANRO Alto Neuroscience, Inc. Common Stock, $0.0001 par value per share 9.9% $77,791,742 +$7,426,527 3,588,180 +11% Commodore Capital LP 31 Mar 2026
EDIT Editas Medicine, Inc. Common Stock, $0.0001 par value per share 9.9% $51,025,650 16,045,802 Commodore Capital LP 26 May 2026
CATX Perspective Therapeutics, Inc. Common Stock, $0.001 par value 9.9% $29,968,780 11,939,753 Commodore Capital LP 02 Feb 2026
ASMB ASSEMBLY BIOSCIENCES, INC. Common Stock, par value $0.001 9.9% $29,281,576 1,615,981 Commodore Capital LP 08 Aug 2025
IKT Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value 9.9% $25,439,441 14,054,940 Commodore Capital LP 31 Mar 2026
SABS SAB BIOTHERAPEUTICS, INC. Common Stock, $0.0001 par value per share 9.9% $9,588,711 4,522,977 Commodore Capital LP 26 Sep 2025
IMUX IMMUNIC, INC. Common Stock, par value $0.0001 9.9% $8,143,574 13,350,121 Commodore Capital LP 17 Feb 2026
ANTX AN2 Therapeutics, Inc. Common Stock, par value $0.00001 per share 9.9% $4,880,614 3,697,435 Commodore Capital LP 09 Mar 2026
VTGN Vistagen Therapeutics, Inc. Common Stock, par value $0.001 per share 9.9% $3,243,796 4,383,508 Commodore Capital LP 31 Dec 2025
KPTI Karyopharm Therapeutics Inc. Common Stock, $0.0001 par value 9.9% $1,170,000 1,950,000 Commodore Capital LP 26 Mar 2026
ELVN Enliven Therapeutics, Inc. Common Stock, par value $0.001 per share 7.7% $217,578,601 -$55,381,810 4,800,940 -20% Commodore Capital LP 31 Mar 2026
PALI PALISADE BIO, INC. Common Stock, par value $0.01 per share 7.2% $21,641,858 +$4,683,194 12,366,776 +28% Commodore Capital LP 31 Mar 2026
Definium Therapeutics, Inc. Common Shares, no par value per share 7.2% 7,428,775 Commodore Capital LP 31 Dec 2025
IPSC Century Therapeutics, Inc. Common Stock, par value $0.0001 per share 7.1% $12,354,782 13,043,478 Commodore Capital LP 09 Jan 2026
LBRX LB PHARMACEUTICALS INC Common Stock, $0.0001 par value per share 6.8% $48,007,461 +$18,190,961 1,972,369 +61% Commodore Capital LP 31 Mar 2026
PEPG PepGen Inc. Common stock, par value $0.0001 per share 6.5% $7,204,750 +$1,498,747 4,475,000 +26% Commodore Capital LP 31 Mar 2026
Research Alliance Corp III Class A Ordinary Shares, par value $0.0001 per share 5.5% 500,000 Commodore Capital LP 20 May 2026
AMLX Amylyx Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share 5.1% $89,213,500 5,650,000 Commodore Capital LP 10 Nov 2025
EYPT EyePoint, Inc. Common Stock, par value $0.001 5.1% $57,077,500 4,250,000 Commodore Capital LP 27 May 2026
RLMD RELMADA THERAPEUTICS, INC. Common stock, $0.001 par value per share 5.1% $40,630,789 5,505,527 Commodore Capital LP 27 Apr 2026
NRIX Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share 4.9% $34,927,708 -$646,292 3,780,055 -1.8% Commodore Capital LP 30 Sep 2025
MRUS Merus N.V. Common Shares, (euro) 0.09 nominal value per share 4.7% $192,112,500 -$12,262,500 3,525,000 -6% Commodore Capital LP 30 Jun 2025
CLDX Celldex Therapeutics, Inc. Common Stock, par value $.001 4.6% $78,343,026 -$8,321,474 3,028,335 -9.6% Commodore Capital LP 30 Sep 2025
TYRA Tyra Biosciences, Inc. Common Stock, $0.0001 par value per share 4.2% $94,743,000 -$34,452,000 2,475,000 -27% Commodore Capital LP 31 Mar 2026
VRDN Viridian Therapeutics, Inc.\DE Common Stock, $0.01 par value 3.9% $69,056,000 -$23,738,000 3,200,000 -26% Commodore Capital LP 30 Sep 2025
NGNE Neurogene Inc. Common Stock, $0.000001 par value 3% $9,169,168 427,866 Commodore Capital LP 30 Jun 2025
CELC Celcuity Inc. Common Stock, $0.001 par value per share 2.9% $12,095,976 1,095,650 COMMODORE CAPITAL LP 31 Dec 2024
CDTX Cidara Therapeutics, Inc. Common Stock, par value $0.0001 per share 2% $56,019,600 -$56,498,400 585,000 -50% Commodore Capital LP 30 Sep 2025
COGT Cogent Biosciences, Inc. Common Stock, $0.001 par value per share 1.8% $99,699,331 -$263,401,363 2,802,905 -73% Commodore Capital LP 31 Dec 2025
TERN Terns Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share 1.4% $52,333,000 -$149,903,000 1,475,000 -74% Commodore Capital LP 31 Dec 2025
NKTX Nkarta, Inc. Common Stock, $0.0001 par value per share 0.5% $742,399 351,848 COMMODORE CAPITAL LP 31 Dec 2024
DRUG BRIGHT MINDS BIOSCIENCES INC. Common Shares, without par value 0.3% $1,685,468 -$43,019,532 18,851 -96% Commodore Capital LP 31 Dec 2025
CRDF Cardiff Oncology, Inc. Common Stock 0% $0 -$21,915,387 0 -100% Commodore Capital LP 30 Jun 2025
SLDB Solid Biosciences Inc. Common Stock $0.001 par value per share 0% $0 -$31,571,500 0 -100% Commodore Capital LP 30 Jun 2025
PCSC Perceptive Capital Solutions Corp Class A Ordinary Shares, par value $0.0001 per share 0% $0 0 Commodore Capital LP 31 Dec 2025

Schedules 13D/G Reported by Commodore Capital LP:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .